ArticleFrontiers in pharmacology2025
Integrated metabolomics and network pharmacology analysis to reveal the mechanisms of Wenshenyang decoction in the treatment of chronic kidney disease.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Challenges and perspectives in traditional Chinese medicine intervention for uremic pruritus: emphasis on blinding, mechanisms, and safety assessment.International urology and nephrology · 2026Article
- Investigation of the improvement effect of Dajianzhong decoction on rats with post-operative ileus based on serum metabolomics and spectrum-effect relationship.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Wenshenyang decoction (WSY) has been shown to have a considerable effect on restoring renal function and improving kidney Yang deficiency syndrome in patients with CKD. However, its mechanism remains unclear. Aims: This study aimed to integrated metabolomics and network pharmacology analysis combined with Materials and methods: Patients were selected from a clinical trial. LC-MS (Liquid chromatography-mass spectrometry) was used to investigate the differential metabolites and pathways. Spearman correlation analysis was performed between differential metabolites and clinical phenotypes. "Drug-component-differential metabolite" network was constructed to predict the core components and hub genes, and validated by molecular docking. On this basis, the effects of core components of WSY on the viability of Human Kidney-2 cells (HK-2) induced by doxorubicin (DOX) was detected by CCK-8, and RT-qPCR (Reverse transcription quantitative polymerase chain reaction) was used to detect the mRNA expression level of hub genes and related targets. Key findings: LC-MS detected 54 differential metabolites, of which 35 metabolites showed up regulated, and 19 decreased. Spearman analysis showed that the differential metabolites were correlated with the clinical phenotype. KEGG (Kyoto Encyclopedia of Genes and Genomes) enrichment analysis showed that WSY mainly affected linoleic acid metabolism, FcεRI signaling pathway, and unsaturated fatty acid biosynthesis. The "Drug-component-differential metabolite" network showed that the core components of WSY were quercetin, luteolin and kaempferol, and the hub genes were PTGS2, AKT1, MMP9, EGFR and MMP2. Molecular docking showed that they had good biological binding capacity. Significance: WSY has multi-component and multi-target properties in the treatment of CKD kidney Yang deficiency syndrome, and its mechanism may be related to anti-inflammatory and anti-fibrotic effects. This study provides a methodological reference for the treatment of CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.